Selegiline
Emsam, Zelapar (selegiline) is a small molecule pharmaceutical. Selegiline was first approved as Selegiline hydrochloride on 1989-06-05. It is used to treat alzheimer disease, attention deficit disorder with hyperactivity, depressive disorder, parkinson disease, and schizophrenia in the USA. The pharmaceutical is active against amine oxidase [flavin-containing] B. In addition, it is known to target amine oxidase [flavin-containing] A.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Emsam, Zelapar (generic drugs available since 1997-04-01, discontinued: Eldepryl)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
emsam | New Drug Application | 2020-05-15 |
selegiline hydrochloride | ANDA | 2023-03-03 |
zelapar | New Drug Application | 2021-06-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
alzheimer disease | EFO_0000249 | D000544 | F03 |
attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
depressive disorder | EFO_1002014 | D003866 | F32.A |
parkinson disease | EFO_0002508 | D010300 | G20 |
schizophrenia | EFO_0000692 | D012559 | F20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 4 | — | 4 |
Healthy volunteers/patients | — | — | — | — | 2 | 1 | 3 | ||
Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | 1 | — | 1 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 1 | — | 1 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cocaine-related disorders | D019970 | F14 | 1 | 4 | 1 | — | — | 6 | |
Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | — | — | 1 | 3 |
Tobacco use disorder | D014029 | F17 | — | 2 | — | — | 1 | 3 | |
Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 | |
Castration-resistant prostatic neoplasms | D064129 | — | 1 | — | — | — | 1 | ||
Cognition disorders | D003072 | — | 1 | — | — | — | 1 | ||
Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | — | — | — | 1 |
Tobacco use cessation | D020340 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | — | — | — | — | 1 |
Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | SELEGILINE |
INN | selegiline |
Description | (-)-selegiline is a selegiline and a terminal acetylenic compound. It has a role as a geroprotector. It is a conjugate base of a (-)-selegiline(1+). |
Classification | Small molecule |
Drug class | Monoamine oxidase (MAO) inhibitors, type B |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C#CCN(C)[C@H](C)Cc1ccccc1 |
Identifiers
PDB | — |
CAS-ID | 14611-51-9 |
RxCUI | 9639 |
ChEMBL ID | CHEMBL972 |
ChEBI ID | 9086 |
PubChem CID | 26757 |
DrugBank | DB01037 |
UNII ID | 2K1V7GP655 (ChemIDplus, GSRS) |
Target
Agency Approved
MAOB
MAOB
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,514 documents
View more details
Safety
Black-box Warning
Black-box warning for: Emsam
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
90,104 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more